Affinia Therapeutics Inc. (AFTX)

Affinia Therapeutics was planning to go public, but the IPO has been withdrawn.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) 8.06M
Net Income (ttm) -39.77M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About AFTX

Affinia Therapeutics is a preclinical stage company pioneering a new class of rationally designed gene therapies with potentially curative benefit in patients with both rare and prevalent devastating diseases. We created our proprietary Affinia Rationally-designed Therapies (ART) platform to develop these novel therapies, focusing on the three key components of a gene therapy: capsids, which are the outer shells of a virus used to deliver the genetic code to tissues to treat a disease; promoters, which control how the cells read the genetic cod... [Read more]

Industry Health Care
Founded 2019
CEO Rick Modi
Employees 63
Stock Exchange NASDAQ
Ticker Symbol AFTX
Full Company Profile

Financial Performance

Financial Statements

News

Gene therapy biotech Affinia Therapeutics files for a $100 million IPO

Affinia Therapeutics, a preclinical biotech developing novel gene therapies for rare diseases and cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

11 months ago - Renaissance Capital

Affinia Therapeutics IPO Registration Document (S-1)

Affinia Therapeutics has filed to go public with an IPO on the NASDAQ.

11 months ago - SEC

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs

Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to...

1 year ago - GLOBE NEWSWIRE